Singh Prachi, Zhang Yuebo, Sharma Pragya, Covassin Naima, Soucek Filip, Friedman Paul A, Somers Virend K
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
ICRC - Department of Cardiovascular Diseases, St. Anne's University Hospital, Brno, Czech Republic.
Physiol Rep. 2018 Jan;6(2). doi: 10.14814/phy2.13566.
Statin use is associated with increased calorie intake and consequent weight gain. It is speculated that statin-dependent improvements in lipid profile may undermine the perceived need to follow lipid-lowering and other dietary recommendations leading consequently to increased calorie intake. However, increases in calorie intake in statin users may also be related to statin-dependent decreases in satiety factors such as leptin, an adipocyte-derived adipokine. The objective of our study was to examine the direct effects of statins on leptin expression. Adipocytes are the main source of circulating leptin. Therefore, we examined the effects of atorvastatin and simvastatin on leptin expression in cultured human white adipocytes. We show that treatment of white adipocytes with simvastatin and atorvastatin decreases leptin mRNA expression (simvastatin: P = 0.008, atorvastatin: P = 0.03) and leptin secretion (simvastatin: P = 0.0001, atorvastatin: P = 0.0001). Both simvastatin and atorvastatin mediate decreases in leptin expression via extracellular-signal-regulated kinases 1/2 and peroxisome proliferator-activated receptor gamma pathways (simvastatin: P = 0.01, atorvastatin: P = 0.026). Additionally, statin treatment also induced expected increases in adiponectin, while decreasing monocyte chemoattractant protein 1 (MCP1) mRNA. Furthermore, statins increased secretion of both total as well as high molecular weight adiponectin while decreasing MCP1 secretion. To conclude, statins act directly on human white adipocytes to regulate adipokine secretion and decrease leptin expression. Leptin is an important satiety factor. Hence, statin-dependent decreases in leptin may contribute, at least in part, to increases in food intake in statin users.
使用他汀类药物与热量摄入增加及随之而来的体重增加有关。据推测,他汀类药物依赖的血脂改善可能会削弱人们对遵循降脂及其他饮食建议的认知需求,从而导致热量摄入增加。然而,他汀类药物使用者热量摄入的增加也可能与他汀类药物依赖的饱腹感因子(如脂肪细胞衍生的脂肪因子瘦素)减少有关。我们研究的目的是检验他汀类药物对瘦素表达的直接影响。脂肪细胞是循环中瘦素的主要来源。因此,我们研究了阿托伐他汀和辛伐他汀对培养的人白色脂肪细胞中瘦素表达的影响。我们发现,用辛伐他汀和阿托伐他汀处理白色脂肪细胞会降低瘦素mRNA表达(辛伐他汀:P = 0.008,阿托伐他汀:P = 0.03)和瘦素分泌(辛伐他汀:P = 0.0001,阿托伐他汀:P = 0.0001)。辛伐他汀和阿托伐他汀均通过细胞外信号调节激酶1/2和过氧化物酶体增殖物激活受体γ途径介导瘦素表达的降低(辛伐他汀:P = 0.01,阿托伐他汀:P = 0.026)。此外,他汀类药物治疗还导致脂联素预期增加,同时降低单核细胞趋化蛋白1(MCP1)mRNA。此外,他汀类药物增加了总脂联素以及高分子量脂联素的分泌,同时降低了MCP1的分泌。总之,他汀类药物直接作用于人白色脂肪细胞以调节脂肪因子分泌并降低瘦素表达。瘦素是一种重要的饱腹感因子。因此,他汀类药物依赖的瘦素降低可能至少部分导致他汀类药物使用者食物摄入量增加。